1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor
  4. P2Y12 Receptor Isoform
  5. P2Y12 Receptor Antagonist

P2Y12 Receptor Antagonist

P2Y12 Receptor Antagonists (6):

Cat. No. Product Name Effect Purity
  • HY-10064
    Ticagrelor
    Antagonist 99.92%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-19638A
    Cangrelor tetrasodium
    Antagonist 99.93%
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
  • HY-108660
    PSB-0739
    Antagonist 98.67%
    PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect.
  • HY-15799
    AZD1283
    Antagonist 99.27%
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.
  • HY-125989B
    2-Methylthio-AMP diTEA
    Antagonist ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
  • HY-10064S
    Ticagrelor-d7
    Antagonist
    Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].